{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:17:38Z","timestamp":1761765458642},"publisher-location":"Boston, MA","reference-count":68,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781461288831"},{"type":"electronic","value":"9781461315957"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1989]]},"DOI":"10.1007\/978-1-4613-1595-7_8","type":"book-chapter","created":{"date-parts":[[2011,9,19]],"date-time":"2011-09-19T07:27:33Z","timestamp":1316417253000},"page":"143-158","source":"Crossref","is-referenced-by-count":5,"title":["Systemic chemotherapy in the management of bladder cancer"],"prefix":"10.1007","author":[{"given":"David M.","family":"Nanus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George J.","family":"Bosl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"8_CR1","first-page":"5","volume":"38","author":"E Silverberg","year":"1988","unstructured":"Silverberg E, Lubera JA: Cancer Statistics 1988. CA 38: 5\u201322, 1988.","journal-title":"CA"},{"key":"8_CR2","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0022-5347(17)51695-X","volume":"130","author":"NM Heney","year":"1983","unstructured":"Heney NM, Ahmed S, Flanagan MJ, et al.: Superficial bladder cancer: Progression and recurrence. J Urol 130: 1083\u20131086, 1983.","journal-title":"J Urol"},{"key":"8_CR3","first-page":"4","volume":"1","author":"WF Whitmore","year":"1983","unstructured":"Whitmore WF: Management of invasive bladder neoplasms. Semin Urol 1: 4\u201310, 1983.","journal-title":"Semin Urol"},{"key":"8_CR4","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0022-5347(17)54638-8","volume":"126","author":"JA Smith","year":"1981","unstructured":"Smith JA, Whitmore WF: Regional lymph node metastasis from bladder cancer. J Urol 126: 591\u2013595, 1981.","journal-title":"J Urol"},{"key":"8_CR5","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/cncr.1980.45.s7.1879","volume":"45","author":"A Yagoda","year":"1980","unstructured":"Yagoda A: Chemotherapy of metastatic bladder cancer. Cancer 45: 1879\u20131888, 1980.","journal-title":"Cancer"},{"key":"8_CR6","first-page":"2775","volume":"37","author":"A Yagoda","year":"1977","unstructured":"Yagoda A: Future implications of phase 2 chemotherapy trials in ninety-five patients with measurable advanced bladder cancer. Cancer Res 37: 2775\u20132280, 1977.","journal-title":"Cancer Res"},{"key":"8_CR7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0094-0143(21)00576-0","volume":"14","author":"CN Sternberg","year":"1987","unstructured":"Sternberg CN, Scher HI: Advances in the treatment of urothelial tract tumours. Urol Clin 14: 373\u2013387, 1987.","journal-title":"Urol Clin"},{"key":"8_CR8","first-page":"301","volume-title":"Developments in Bladder Cancer","author":"AT Oosterom Van","year":"1986","unstructured":"Van Oosterom AT, Akaza H, Hall R, et al.: Response criteria phase II\/phase III bladder cancer. In: Developments in Bladder Cancer, Denis L, Nijima T, Prout G, Schroeder FH (eds). AR Liss, New York, 1986, 301\u2013310."},{"key":"8_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/BF00326931","volume":"2","author":"G Bosl","year":"1985","unstructured":"Bosl G: Status and prospects in the treatment of disseminated germ-cell tumours. World J Urol 2: 38\u201342, 1985.","journal-title":"World J Urol"},{"key":"8_CR10","first-page":"3404","volume":"43","author":"GJ Bosl","year":"1983","unstructured":"Bosl GJ, Geller NL, Cirrincione C, et al.: Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 43: 3404\u20133407, 1983.","journal-title":"Cancer Res"},{"key":"8_CR11","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/1097-0142(19870801)60:3+<574::AID-CNCR2820601524>3.0.CO;2-C","volume":"60","author":"A Yagoda","year":"1987","unstructured":"Yagoda A: Chemotherapy of urothelial tract tumours. Cancer 60: 574\u2013585, 1987.","journal-title":"Cancer"},{"key":"8_CR12","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.1985.3.11.1448","volume":"3","author":"A Yagoda","year":"1985","unstructured":"Yagoda A: Progress in treatment of advanced urothelial tract tumours. J Clin Oncol 3:1448\u20131450, 1985.","journal-title":"J Clin Oncol"},{"key":"8_CR13","first-page":"239","volume":"3","author":"HI Scher","year":"1985","unstructured":"Scher HI, Sternberg CN: Chemotherapy of urologic malignancies. Semin Urol 3: 239\u2013280, 1985.","journal-title":"Semin Urol"},{"key":"8_CR14","first-page":"917","volume":"60","author":"A Yagoda","year":"1976","unstructured":"Yagoda A, Watson RC, Gonzales-Vitale JC, et al.: Cisdichlorodiammineplatinum (II) in advanced bladder cancer. Cancer Treat Rep 60: 917\u2013923, 1976.","journal-title":"Cancer Treat Rep"},{"key":"8_CR15","first-page":"60","volume":"1","author":"A Yagoda","year":"1983","unstructured":"Yagoda A: Chemotherapy for advanced urothelial cancer. Semin Urol 1: 60\u201374, 1983.","journal-title":"Semin Urol"},{"key":"8_CR16","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/1097-0142(19810315)47:6<1246::AID-CNCR2820470603>3.0.CO;2-G","volume":"47","author":"RB Natale","year":"1981","unstructured":"Natale RB, Yagoda A, Watson RC, et al.: Methotrexate: An active drug in bladder cancer. Cancer 47: 1246\u20131250, 1981.","journal-title":"Cancer"},{"key":"8_CR17","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0022-5347(17)50459-0","volume":"131","author":"RTD Oliver","year":"1984","unstructured":"Oliver RTD, England HR, Risdon DA, et al.: Methotrexate in the treatment of primary and recurrent primary transitional cell carcinoma. J Urol 131: 483\u2013485, 1984.","journal-title":"J Urol"},{"key":"8_CR18","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/1097-0142(197701)39:1<279::AID-CNCR2820390143>3.0.CO;2-K","volume":"39","author":"A Yagoda","year":"1977","unstructured":"Yagoda A, Watson RC, Whitmore WF, et al.: Adriamycin in advanced urinary tract cancer. Cancer 39: 279\u2013285, 1977.","journal-title":"Cancer"},{"key":"8_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/1097-0142(197307)32:1<1::AID-CNCR2820320101>3.0.CO;2-X","volume":"32","author":"RM O\u2019Bryan","year":"1973","unstructured":"O\u2019Bryan RM, Luce JK, Talley RW, et al.: Phase II evaluation of Adriamycin in human neoplasia. Cancer 32: 1\u20138, 1973.","journal-title":"Cancer"},{"key":"8_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/00000421-198304000-00014","volume":"6","author":"R Gagliano","year":"1983","unstructured":"Gagliano R, Levin H, El-Bolkainy MN, et al.: Adriamycin versus Adriamycin plus cis-diammine dichloroplatinum in advanced transitional cell bladder carcinoma. Am J Clin Oncol 6: 215\u2013218, 1983.","journal-title":"Am J Clin Oncol"},{"key":"8_CR21","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"D Hoff Von","year":"1979","unstructured":"Von Hoff D, Layard DW, et al.: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710\u2013717, 1979.","journal-title":"Ann Intern Med"},{"key":"8_CR22","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/1097-0142(19820801)50:3<435::AID-CNCR2820500309>3.0.CO;2-B","volume":"50","author":"MA Blumenreich","year":"1982","unstructured":"Blumenreich MA, Yagoda A, Natale RB, et al.: Phase II trial of vinblastine sulfate for metastatic urothelial tract tumours. Cancer 50: 435\u2013438, 1982.","journal-title":"Cancer"},{"key":"8_CR23","first-page":"84","volume":"240","author":"ED Crawford","year":"1983","unstructured":"Crawford ED, Saiers JH, Baker LH: Treatment of metstatic bladder cancer wtih gallium nitrate. 13th International Congress of Chemotherapy. 240: 12.1.7\/A-4, 84, 1983.","journal-title":"13th International Congress of Chemotherapy"},{"key":"8_CR24","first-page":"1311","volume":"70","author":"BJ Foster","year":"1986","unstructured":"Foster BJ, Clagett-Carr K, Hoth D, et al.: Gallium nitrate: The second metal with clinical activity. Cancer Treat Rep 70: 1311\u20131319, 1986.","journal-title":"Cancer Treat Rep"},{"key":"8_CR25","first-page":"101","volume":"5","author":"SP Creekmore","year":"1986","unstructured":"Creekmore SP, Waters WB, Vogelzang NJ, et al.: Antitumor activity of 24-hour CBCDA infusions in metastatic transitional cell carcinoma. Proc Am Soc Clin Oncol 5: 101, 1986.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"8_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1464-410X.1986.tb05423.x","volume":"58","author":"RTD Oliver","year":"1986","unstructured":"Oliver RTD, Kwok HK, Highman WJ, et al.: Methotrexate, cisplatin and carboplatin as single agents and in combination for metstatic bladder cancer. Br J Urol 58: 1\u20135, 1986.","journal-title":"Br J Urol"},{"key":"8_CR27","first-page":"166","volume":"6","author":"MS Soloway","year":"1979","unstructured":"Soloway MS, Murphy WM: Experimental chemotherapy of bladder cancer \u2014 systemic and intravesical. Semin Oncol 6: 166\u2013183, 1979.","journal-title":"Semin Oncol"},{"issue":"Suppl.","key":"8_CR28","first-page":"S9","volume":"2","author":"A Yagoda","year":"1983","unstructured":"Yagoda A: Phase II trials in patients with urothelial tract tumour: Memorial Sloan Kettering Cancer Center. Cancer Chemother Pharmacol 2(Suppl.): S9\u2013S12, 1983.","journal-title":"Cancer Chemother Pharmacol"},{"key":"8_CR29","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/1097-0142(19830901)52:5<767::AID-CNCR2820520502>3.0.CO;2-P","volume":"52","author":"MS Soloway","year":"1983","unstructured":"Soloway MS, Einstein A, Corder MP, et al.: A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial tract tumors. Cancer 52: 767\u2013772, 1983.","journal-title":"Cancer"},{"key":"8_CR30","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1200\/JCO.1987.5.3.450","volume":"5","author":"WJM Hrushesky","year":"1987","unstructured":"Hrushesky WJM, Roemeling RV, Wood PA, et al.: High-dose systemic therapy for metastatic bladder cancer. J Clin Oncol 5: 450\u2013455, 1987.","journal-title":"J Clin Oncol"},{"key":"8_CR31","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1001\/jama.238.21.2282","volume":"238","author":"JJ Sternberg","year":"1977","unstructured":"Sternberg JJ, Bracken RB, Handel PB, et al.: Combination chemotherapy (CISCA) for advanced urinary tract carcinoma: A preliminary report. JAMA 238: 2282\u20132287, 1977.","journal-title":"JAMA"},{"key":"8_CR32","first-page":"137","volume":"21","author":"ML Samuels","year":"1980","unstructured":"Samuels ML, Logothetis CJ, Trindade A, et al.: Cytoxan, Adriamycin and cisplatin (CISCA) in metastatic bladder cancer. Proc Am Assoc Cancer Res 21: 137, 1980.","journal-title":"Proc Am Assoc Cancer Res"},{"key":"8_CR33","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0022-5347(17)47240-5","volume":"134","author":"CJ Logothetis","year":"1985","unstructured":"Logothetis CJ, Samuels ML, Ogden S, et al.: Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumours with or without nodal metastases. J Urol 134: 460\u2013464, 1985.","journal-title":"J Urol"},{"key":"8_CR34","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0022-5347(17)51401-9","volume":"138","author":"S Schwartz","year":"1983","unstructured":"Schwartz S, Yagoda A, Natale RB, et al.: Phase II trial of sequentially administered cisplatin, cyclophosphamide and doxorubicin for urothelial tract tumours. J Urol 138: 681\u2013685, 1983.","journal-title":"J Urol"},{"key":"8_CR35","first-page":"897","volume":"65","author":"M Campbell","year":"1981","unstructured":"Campbell M, Baker LH, Opipari M, et al.: Phase II trial with cis-dichlorodiammine platinum, Adriamycin and cyclophosphamide in the treatment of urothelial transitional cell carcinoma. Cancer Treat Rep 65: 897\u2013899, 1981.","journal-title":"Cancer Treat Rep"},{"key":"8_CR36","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1200\/JCO.1985.3.4.539","volume":"3","author":"JD Khandekar","year":"1985","unstructured":"Khandekar JD, Elson PJ, DeWys WD, et al.: Comparitive activity and toxicity of cisdiamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide and DDP in disseminated transitional cell carcinoma of the urinary tract. J Clin Oncol 3: 539\u2013545, 1985.","journal-title":"J Clin Oncol"},{"key":"8_CR37","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0022-5347(17)44167-X","volume":"137","author":"M Troner","year":"1987","unstructured":"Troner M, Birch R, Omura GA, et al.: Phase III comparison of cisplatinum alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: A Southeastern Cancer Study Group trial. J Urol 137: 660\u2013662, 1987.","journal-title":"J Urol"},{"key":"8_CR38","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S0022-5347(17)49106-3","volume":"133","author":"T Ahmed","year":"1985","unstructured":"Ahmed T, Yagoda A, Needles B, et al.: Vinblastine and methotrexate for advanced bladder cancer. J Urol 133: 602\u2013604, 1985.","journal-title":"J Urol"},{"key":"8_CR39","first-page":"503","volume":"67","author":"IF Tannock","year":"1983","unstructured":"Tannock IF: Methotrexate and mitomycin for patients with metastatic transitional cell carcinoma of the urinary tract. Cancer Treat Rep 67: 503\u2013504, 1983.","journal-title":"Cancer Treat Rep"},{"key":"8_CR40","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/1097-0142(19830115)51:2<216::AID-CNCR2820510208>3.0.CO;2-I","volume":"51","author":"I Tannock","year":"1983","unstructured":"Tannock I, Gospadarowicz M, Evans WF: Chemotherapy for metastatic transitional cell carcinoma of the urinary tract. A prospective trial of methotrexate, Adriamycin, and cyclo-phophamide (MAC) with cis-platinum for failure. Cancer 51: 216\u2013219, 1983.","journal-title":"Cancer"},{"key":"8_CR41","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0022-5347(17)44168-1","volume":"137","author":"G Stoter","year":"1987","unstructured":"Stoter G, Splinter TAW, Child JA, et al.: Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J Urol 137: 663\u2013667, 1987.","journal-title":"J Urol"},{"key":"8_CR42","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1464-410X.1985.tb06348.x","volume":"57","author":"J Carmichael","year":"1985","unstructured":"Carmichael J, Cornbleet M, MacDougall S, et al.: Cisplatin and methotrexate in the treatment of transitional cell carcinoma of the urinary tract. Br J Urol 57: 299\u2013302, 1985.","journal-title":"Br J Urol"},{"key":"8_CR43","first-page":"426","volume":"5","author":"BL Hillcoat","year":"1986","unstructured":"Hillcoat BL, Rahhavan D, The Australian Bladder Cancer Study Group: A randomized comparison of cisplatin (C) versus cisplatin and methotrexate (C + M) in advanced bladder cancer. Proc Am Soc Clin Oncol 5: 426, 1986.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"8_CR44","first-page":"104","volume":"5","author":"RB Natale","year":"1986","unstructured":"Natale RB, Grossman HB, Crawford ED, et al.: Combination cisplatin and dichlorometho-trexate in advanced bladder cancer: A Southwest Oncology Group (SWOG) study. Proc Am Soc Clin Oncol 5: 104, 1986.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"8_CR45","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0022-5347(17)48996-8","volume":"133","author":"CN Sternberg","year":"1985","unstructured":"Sternberg CN, Yagoda A, Scher HI, et al.: Preliminary results of M-VAC (methtrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinima of the urothelium. J Urol 133: 403\u2013407, 1985.","journal-title":"J Urol"},{"key":"8_CR46","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0022-5347(17)42494-3","volume":"139","author":"CN Sternbeg","year":"1988","unstructured":"Sternbeg CN, Yagoda A, Scher HI, et al.: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinima of the urothelium. J Urol 139: 461\u2013469, 1988.","journal-title":"J Urol"},{"key":"8_CR47","first-page":"105","volume":"6","author":"H Scher","year":"1987","unstructured":"Scher H, Reuter V, Sternberg C, et al.: Pathologic response to M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) urothelial tract tunors. Proc Am Soc Clin Oncol 6: 105, 1987.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"8_CR48","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1200\/JCO.1985.3.11.1463","volume":"3","author":"WG Harker","year":"1985","unstructured":"Harker WG, Meyers FJ, Freiha FS, et al.: Cisplatin, methotrexate and vinblastine (CMV): An effective chemotherapy regimen for transitional cell carcinima of the urinary tract. J Clin Oncol 3: 1463\u20131470, 1985.","journal-title":"J Clin Oncol"},{"key":"8_CR49","first-page":"104","volume":"6","author":"C Sternberg","year":"1987","unstructured":"Sternberg C, Geller N, Scher H, et al.: Prognostic factors for survival of patients with advanced urothelial cancer treated with M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Proc Am Soc Clin Oncol 6: 104, 1987.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"8_CR50","first-page":"183","volume-title":"Advances in Urologic Oncology","author":"FJ Meyers","year":"1987","unstructured":"Meyers FJ, Palmer JM, Hannigan JF: Chemotherapy of disseminated transitional cell carcinoma. In: Advances in Urologic Oncology, Williams RD (ed). Macmillian Pulishing, New York, 1987, pp. 183\u2013192."},{"issue":"Suppl.","key":"8_CR51","first-page":"110","volume":"23","author":"AB Einstein","year":"1983","unstructured":"Einstein AB, Shipley W, Coombs J, et al.: Cis-platin as adjunctive treatment for invasive bladder carcinoma: Tolerance and toxicities. Urology 23(Suppl.): 110\u2013117, 1983.","journal-title":"Urology"},{"key":"8_CR52","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/0090-4295(87)90095-1","volume":"29","author":"MS Soloway","year":"1987","unstructured":"Soloway MS: Is there a role for induction therapy for locally advanced bladder cancer? Urology 29: 577\u2013583, 1987.","journal-title":"Urology"},{"key":"8_CR53","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0090-4295(85)90532-1","volume":"25","author":"DE Hill","year":"1985","unstructured":"Hill DE, Ford KS, Soloway MS: Radical cystectomy and adjuvant chemotherapy. Urology 25: 151\u2013154, 1985.","journal-title":"Urology"},{"key":"8_CR54","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/0090-4295(84)90387-X","volume":"24","author":"DG Skinner","year":"1984","unstructured":"Skinner DG, Daniels JR, Leiskovsky G: Current status of adjuvant chemotherapy after radical cystectomy for deeply invasive bladder cancer. Urology 24: 46\u201352, 1984.","journal-title":"Urology"},{"issue":"Suppl. 1","key":"8_CR55","first-page":"187","volume":"65","author":"Y Soquet","year":"1981","unstructured":"Soquet Y: Surgery and adjuvant chemotherapy with high dose methotrexate and folinic acid resuce for infiltrating tumours of the bladder. Cancer Treat Rep 65(Suppl. 1): 187\u2013189, 1981.","journal-title":"Cancer Treat Rep"},{"key":"8_CR56","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/j.1464-410X.1984.tb06142.x","volume":"56","author":"RR Hall","year":"1984","unstructured":"Hall RR, Newling DWW, Ramsden PD, et al.: Treatment of invasive bladder cancer by local resection and high dose methotrexate. Br J Urol 56: 668\u2013672, 1984.","journal-title":"Br J Urol"},{"issue":"Suppl.","key":"8_CR57","first-page":"912","volume":"31","author":"A Yagoda","year":"1988","unstructured":"Yagoda A: Neoadjuvant chemotherapy in bladder cancer. Urol 31(Suppl.): 912, 1988.","journal-title":"Urol"},{"key":"8_CR58","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0022-5347(17)48995-6","volume":"133","author":"D Raghavan","year":"1985","unstructured":"Raghavan D, Pearson B, Duval P, et al.: Initial intravenous cis-platinum therapy: Improved management for high risk bladder cancer. J Urol 133: 399\u2013402, 1985.","journal-title":"J Urol"},{"key":"8_CR59","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0022-5347(17)49938-1","volume":"132","author":"WU Shipley","year":"1984","unstructured":"Shipley WU, Coombs LJ, Einstein AB, et al.: Cisplatin and full dose irrdiation for patients with invasive bladder carcinoma: A preliminary report of tolerance and local response. J Urol 132: 899\u2013903, 1984.","journal-title":"J Urol"},{"key":"8_CR60","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1002\/1097-0142(19831215)52:12<2205::AID-CNCR2820521205>3.0.CO;2-L","volume":"52","author":"HW Herr","year":"1983","unstructured":"Herr HW, Yagoda A, Batata M, et al.: Planned preoperative cisplatin and radiation therapy for locally advanced bladder cancer. Cancer 52: 2205\u20132208, 1983.","journal-title":"Cancer"},{"key":"8_CR61","first-page":"103","volume":"5","author":"FM Torti","year":"1986","unstructured":"Torti FM, Phillips TL, Lum BL, et al.: Effect of preoperative cisplatin (CDDP) nd radiation therapy (XRT) on downstaging of invasive bladder cancer: A NCOG study. Proc Am Soc Clin Oncol 5: 103, 1986.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"8_CR62","first-page":"99","volume":"5","author":"C Coppin","year":"1986","unstructured":"Coppin C, Brown E, the GU Study Group: Concurrent cisplatin and radiation for locally advanced bladder cancer: A pilot study suggesting improved survival. Proc Am Soc Clin Oncol 5: 99, 1986.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"8_CR63","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1001\/jama.258.7.931","volume":"258","author":"Wu Shipley","year":"1987","unstructured":"Shipley Wu, Prout GB, Einstein AB, et al.: Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 258: 931\u2013935, 1987.","journal-title":"JAMA"},{"key":"8_CR64","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0022-5347(17)42495-5","volume":"139","author":"HI Scher","year":"1988","unstructured":"Scher HI, Yagoda A, Herr HW, et al.: Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol 139: 470\u2013474, 1988.","journal-title":"J Urol"},{"key":"8_CR65","first-page":"111","volume":"5","author":"SD Simon","year":"1986","unstructured":"Simon SD, Srougi M: Systemic M-VAC for primary treatment of locally invasive transitional cell carcinoma of the bladder (TCCB): A pilot study. Proc Am Soc Clin Oncol 5:111, 1986.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"8_CR66","first-page":"108","volume":"6","author":"RM Bukowski","year":"1987","unstructured":"Bukowski RM, Montie JE, Pontes EJ: Neodjuvant chemotherapy of loclly advanced transitional cell carcinoma of the bladder \u2014 results of a phase II trial and followup. Proc Am Soc Clin Oncol 6: 108, 1987.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"8_CR67","first-page":"110","volume":"6","author":"A Veronesi","year":"1987","unstructured":"Veronesi A, Dal V, Do A, et al.: Presurgery chemotherapy (CT) in locally advanced bladder carcinoma: A feasible and possibly effective approach. Proc Am Soc Clin Oncol 6: 110, 1987.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"8_CR68","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0022-5347(17)42496-7","volume":"139","author":"HI Scher","year":"1988","unstructured":"Scher HI, Yagoda A, Herr HW, et al.: Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumours. J Urol 139: 475\u2013477, 1988.","journal-title":"J Urol"}],"container-title":["Cancer Treatment and Research","Urologic Oncology"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4613-1595-7_8.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T14:19:03Z","timestamp":1638713943000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4613-1595-7_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989]]},"ISBN":["9781461288831","9781461315957"],"references-count":68,"URL":"https:\/\/doi.org\/10.1007\/978-1-4613-1595-7_8","relation":{},"ISSN":["0927-3042"],"issn-type":[{"type":"print","value":"0927-3042"}],"subject":[],"published":{"date-parts":[[1989]]}}}